Hydroxychloroquine (HCQ) - Autophagy and TLR9 Inhibitor. CAS# 747-36-4 Catalog No.:M60302-10S Impact of a baseline polymorphism

Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor

and SMARCA2 (at 10 µM)

Tasquinimod

The SMARC family A (SMARCA) members SMARCA2 (also known as BRM) and SMARCA4 (also known as BRG1) are helicases that contain structurally-related bromodomains for binding acetylated lysine residues on target proteins

Smiles: COC1=CC=CC=C1S(=O)(=O)NC1=CC2CN(C)C(=O)NC=2C=C1

Hydroxychloroquine (HCQ) - Autophagy and TLR9 Inhibitor. CAS# 747-36-4 Catalog No.:M60302-10S Impact of a baseline polymorphismHydroxychloroquine (HCQ), CAS No. 747 36 4, is a potent autophagy inhibitor and TLR9 inhibitor. It prevents lysosomal acidification, thereby interfering with a key step in the autophagic process. In cancer cells, HCQ treatment has been shown to cause increased apoptosis, tumor regression, and delay in tumor recurrence. HCQ was an effective growth inhibitor of human RCC cell lines, inhibiting growth, promoting apoptosis, and effecting cellular